Aduhelm and an expensive failure to launch

Biogen’s treatment for Alzheimer’s was initially regarded as a major treatment breakthrough. Now, only three years later, Ben Hargreaves finds that the abortive launch holds lessons across the industry – from interactions with the regulator to how to price a product at launch.